INTRODUCTION
============

Liver transplantation (LT) is the optimal therapy for patients with hepatocellular carcinoma (HCC) with cirrhosis because it treats both the tumor and the underlying liver disease.[@b1-gnl-10-604]--[@b3-gnl-10-604] Unfortunately, HCC recurrence is reported to be as high as 40% after LT and remains the major cause of death.[@b4-gnl-10-604],[@b5-gnl-10-604]

Since the first LT performed by Thomas Starzl in 1963, steroids have become the gold standard, together with calcineurin inhibitors, for immunosuppression after LT. However, long-term steroid use may facilitate the proliferation and spread of malignant cells.[@b6-gnl-10-604] It has been reported that steroids play an important role in tumor recurrence after LT for HCC.[@b7-gnl-10-604] In addition, the numerous side effects of steroids, such as infection, obesity, hypertension and diabetes mellitus, have urged the need to avoid or limit steroid usage.[@b8-gnl-10-604]--[@b10-gnl-10-604]

In the past decade, several studies have evaluated the feasibility of steroid-free protocols after LT. Most of these studies have focused on hepatitis C virus-related liver disease.[@b11-gnl-10-604]--[@b20-gnl-10-604] However, hepatitis B virus (HBV) infection is the leading cause of liver cirrhosis and end-stage liver disease in China, and the possible role of a steroid-free protocol in HBV-related HCC recurrence has rarely been evaluated.

In this study, we evaluated the safety and efficacy of steroid-free immunosuppression in patients undergoing LT for HBV-related HCC.

MATERIALS AND METHODS
=====================

1. Patients
-----------

From April 2009 to June 2011, 66 HBV-related HCC patients who underwent LT at the First Affiliated Hospital, Zhejiang University School of Medicine were enrolled in the steroid-free group. All of the recipients in the steroid-free group received methylprednisolone (1,000 mg during the operation) and basiliximab (20 mg during the operation and another 20 mg at 4 days after LT). The steroid-free patients were matched at a 1:2 ratio, by sex, age, donor source, Model for End-stage Liver Disease score, body mass index, α-fetoprotein level and tumor characteristics, with control patients receiving the standard protocol as described previously (methylprednisolone, 1 g on the first day and prednisolone, 20 mg tapered to 0 mg within the first 3 months)[@b21-gnl-10-604] from January 2006 to April 2009 (steroid group, n=132). All the recipients were administered tacrolimus after LT, with a target serum trough level of 10 to 12 ng/mL during the first month and 8 to 10 ng/mL from the second month. Mycophenolate mofetil was prescribed for 1 year at a dose of 0.5 to 1.0 g/day.

In the steroid-free group, 33 recipients fulfilled the Milan criteria[@b22-gnl-10-604] (subgroup SF1) and 33 exceeded the Milan criteria (subgroup SF2). In the steroid group, 53 recipients fulfilled the Milan criteria (subgroup S1) and 79 exceeded the Milan criteria (subgroup S2).

All of these recipients received preoperative antiviral treatments, including monotherapy of nucleoside analogs (lamivudine or entecavir) and multiple therapies of nucleoside analogs (lamivudine plus adefovir) and had an HBV DNA-negative status prior to LT. The main patient clinical characteristics are summarized in [Table 1](#t1-gnl-10-604){ref-type="table"}. All patients received lamivudine combined with low-dose hepatitis B immune globulin therapy after LT, as described previously.[@b23-gnl-10-604] Enhanced computed tomography images and abdominal ultrasonography were performed every 3 to 6 months for HCC recurrence surveillance.

Each organ donation and transplantation strictly followed the guidelines of the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (approval number: 2013-12), the current regulation of the Chinese government and the Declaration of Helsinki 2004. Informed consent was obtained from all patients.

2. Data collection
------------------

HBV recurrence was defined by the reoccurrence of serum HBV surface antigens. Acute rejection (AR) was identified by liver biopsies according to the presence of at least two of the three following criteria according to the Banff classification: portal inflammatory infiltration, endothelialitis, and bile duct damage.[@b24-gnl-10-604],[@b25-gnl-10-604] The Milan criteria were defined as follows: patients with a single tumor ≤5 cm or no more than three tumors, each no larger than 3 cm.[@b22-gnl-10-604] New-onset diabetes mellitus (NODM) was defined as a fasting glucose level of at least 7 mmol/L (126 mg/dL) or a nonfasting glucose level of at least 11.1 mmol/L (200 mg/dL) confirmed on at least two occasions or a need for anti-diabetic drugs persisting beyond the first month but within the first year after transplantation.[@b21-gnl-10-604],[@b26-gnl-10-604] Hypertension was defined as blood pressure greater than 140/90 mm Hg on two consecutive visits and/or the need for antihypertensive therapy. Hyperlipidemia was defined as serum triglycerides ≥150 mg/dL (1.69 mmol/L), serum cholesterol ≥200 mg/dL (5.17 mmol/L), or a need for pharmacological treatment 2 months after LT.[@b27-gnl-10-604] Early renal dysfunction (ERD) was defined as serum creatinine ≥2 mg/dL and/or the need for renal replacement therapy in the first posttransplant week. Early allograft dysfunction (EAD) was defined by the presence of at least one of the following characteristics: total bilirubin \>10 mg/dL, prothrombin time ≥17 seconds and hepatic encephalopathy from day 2 to day 7 posttransplantation.[@b28-gnl-10-604]

3. Statistical analysis
-----------------------

Quantitative variables are expressed as the mean±standard deviation or median and range depending on the distribution. Categorical variables are presented as values and percentages. Student t-test was used to compare quantitative variables. Chi-square test was used to compare categorical variables. The Kaplan--Meier method and log-rank test were used for survival analysis. SPSS version 11.0 (SPSS Inc., Chicago, IL, USA) was used to complete all the analyses, and a p-value less than 0.05 was considered to be statistically significant (two-tailed test).

RESULTS
=======

1. Patient characteristics
--------------------------

There were no significant differences in age, sex, primary disease, comorbidity, or operation type between the two groups. The tumor characteristics, including size, number, histological differentiation, and vascular invasion did not differ significantly between the two groups ([Table 1](#t1-gnl-10-604){ref-type="table"}). Compared with the steroid group, the steroid-free group showed significantly lower serum alanine transaminase and aspartate transaminase during the first two post-transplant weeks ([Fig. 1](#f1-gnl-10-604){ref-type="fig"}).

2. HCC recurrence and survival
------------------------------

There were no differences in the 1-year (83.3% vs 97.0%, p=0.067), 3-year (65.4% vs 75.8%, p=0.067), or 5-year (56.3% vs 70.7%, p=0.067) patient survival rates or the 1-year (62.1% vs 72.7%, p=0.067), 3-year (49.8% vs 63.6%, p=0.067), or 5-year (48.6% vs 63.6%, p=0.067) tumor-free survival rates between the steroid and steroid-free groups, respectively ([Fig. 2](#f2-gnl-10-604){ref-type="fig"}). Subgroup SF1 showed the highest 1-year, 3-year, and 5-year overall (p\<0.001) and tumor-free (p\<0.001) survival rates in the four subgroups ([Fig. 3A and B](#f3-gnl-10-604){ref-type="fig"}).

3. HBV recurrence
-----------------

Post-transplant HBV recurrence was observed among 10.1% of the patients (20/198). The mean interval for the development of HBV recurrence was 6.36±4.32 months (range, 2.5 to 15.5 months). The HBV recurrence rate was 13.6% in the steroid group (18/132), but only 3.0% in the steroid-free group (2/66) (p=0.020) ([Table 2](#t2-gnl-10-604){ref-type="table"}).

4. Other posttransplant complications
-------------------------------------

There were no significant differences in the incidences of AR (6.1% vs 3.0%, p=0.359), hyperlipidemia (5.3% vs 3.0%, p=0.469), viral infection (2.3% vs 3.0%, p=0.742), tuberculosis infection (0.76% vs 1.5%, p=0.615), bacterial infection (4.5% vs 9.1%, p=0.206), fungus infection (2.3% vs 3.0%, p=0.749), new-onset hypertension (4.5% vs 1.5%, p=0.276), ERD (8.3% vs 4.5%, p= 0.327) and EAD (4.5% vs 3.0%, p=0.610) between the steroid and steroid-free groups, respectively ([Table 2](#t2-gnl-10-604){ref-type="table"}).

DISCUSSION
==========

Steroids have long been considered a linchpin in the prevention and treatment of rejection. However, there are well-known steroid-related adverse effects that result in significant morbidity, including hypertension, diabetes mellitus, hyperlipidemia and obesity, leading to increased cardiovascular risk and infectious complications. The adverse effects of long-term steroid use have stimulated interest in the feasibility of steroid-free maintenance immunosuppressive regimens.[@b8-gnl-10-604]--[@b10-gnl-10-604] Our result demonstrated that a steroid-free protocol was safe in patients undergoing LT for HBV-related HCC. Liver function recovered well during the first 2 posttransplant weeks.

As we know, the prevention of rejection is the initial purpose of using steroids. Steroids inhibit prostaglandin synthesis, inhibiting interleukin 1 (IL-1) transcription and IL-1-dependent lymphocyte activation, stabilizing lysosomal membranes and reducing histamine and bradykinin release.[@b29-gnl-10-604] Safety is the premise of a steroid-free immunosuppressive regimen. Early steroid avoidance in LT showed a high incidence of AR.[@b30-gnl-10-604] An immunosuppressive regimen with a humanized IL-2 receptor (IL-2R) inhibitor has been shown to achieve very low rates of AR.[@b15-gnl-10-604],[@b31-gnl-10-604],[@b32-gnl-10-604] In this study, we also used a humanized IL-2R inhibitor called basiliximab in the steroid-free group and detected no difference in the AR rate between the two groups, a finding that is consistent with that of many previous studies.[@b33-gnl-10-604],[@b34-gnl-10-604]

One important finding of this study is that the incidence of HCC recurrence did not decrease significantly in the steroid-free immunosuppression recipients. We found that both the tumor-free survival and patient overall survival were similar in patients receiving steroid-free immunosuppression compared to those with a steroid protocol. A recent study in China revealed that HCC patients with steroid avoidance achieved a lower tumor recurrence rate after LT than those with steroids withdrawn after 14 days, 3 months or 6 months.[@b20-gnl-10-604] The latter finding is inconsistent with the results of our study. At First Affiliated Hospital, the patients in the steroid-group received steroids for only 3 months; this situation could be viewed as an early steroid withdrawal protocol because steroids are administered for a longer time at many other centers.

The mechanism underlying how steroids contribute to tumor recurrence is not well established. Steroids may reduce the potency of the immune inflammatory response[@b35-gnl-10-604],[@b36-gnl-10-604] or inhibit neutrophil-mediated tumor cell apoptosis, thereby promoting the growth of tumor cells.[@b37-gnl-10-604] In our study, the highest overall and tumor-free survival were observed in the patients fulfilling the Milan criteria using an immunosuppressive regimen without steroids. This phenomenon revealed that strictly selected HCC patients with steroid avoidance would achieve a good prognosis.

Another important finding is that steroid-free immunosuppression might reduce HBV recurrence. In China, a large proportion of LT patients have HBV-related liver disease. Nevertheless, 10% of LT patients with underlying HBV experience a recurrence.[@b38-gnl-10-604],[@b39-gnl-10-604] A study conducted in Korea obtained the outcome that HBV recurrence rates in patients who underwent the steroid-free protocol were much lower than those in patients who underwent the steroid protocol; analysis of the interaction between steroid pulse therapy and HBV recurrence revealed that the HBV has a corticosteroid receptor that promotes virus replication.[@b40-gnl-10-604] Our study showed similar results. Steroid-free immunosuppression may help reduce the high HBV recurrence rate after LT.

In this study, there were no significant differences in hypertension, infection, NODM and hyperlipidemia between the two groups. The side effects of steroids have been observed in other studies. In one study, the incidence of early post-transplant diabetes mellitus (DM), hypertension and infection were lower in the steroid early avoidance recipients. No differences were found in the incidence of hypertension and hyperlipidemia between the steroid early avoidance and standard groups.[@b19-gnl-10-604] In another study, the incidence of hypertension, hyperglycemia, and DM were significant lower in steroid-free recipients,[@b20-gnl-10-604] demonstrating that the effect of steroids on metabolic complications are still controversial.

In summary, an immunosuppressive regimen without steroids could be safe and feasible for HBV-related HCC patients after LT with a reduction in HBV recurrence. It seems that patients fulfilling the Milan criteria may benefit more from steroid-free immunosuppression according to the survival rates found.
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![(A--D) Comparison of post-liver transplantation liver and kidney function. Compared with the steroid group, the steroid-free group showed significantly lower serum alanine transaminase (ALT), aspartate transaminase (AST), and blood urea nitrogen (BUN) levels during the first 2 post-transplant weeks. The creatinine (Cr) level did not differ significantly between the two groups. \*p\<0.05, ^†^p\<0.01.](gnl-10-604f1){#f1-gnl-10-604}

![Between-group comparison of the cumulative patient (A) and tumor-free (B) survival rates. Differences in the overall survival curves of patients in the steroid-free group and patients in the steroid group did not achieve statistical significance (1-year, 83.3% vs 97.0%; 3-year, 65.4% vs 75.8%; 5-year, 56.3% vs 70.7%, respectively; p=0.067 for all). Additionally, the difference in the tumor-free survival curves of patients in the steroid-free group and patients in the steroid group did not reach the level of statistical significance (1-year, 62.1% vs 72.7%; 3-year, 49.8% vs 63.6%; 5-year, 48.6% vs 63.6%, respectively; p=0.067 for all).](gnl-10-604f2){#f2-gnl-10-604}

![Comparison of the cumulative patient (A) and tumor-free (B) survival between the patients who fulfilled and exceeded the Milan criteria. The patients who fulfilled the Milan criteria in the steroid-free group (subgroup SF1) had an improved prognosis compared with the following patients: patients who exceeded the Milan criteria in the steroid-free group (subgroup SF2), patients who fulfilled the Milan criteria in the steroid group (subgroup S1), and patients who exceeded the Milan criteria in the steroid group (subgroup S2).](gnl-10-604f3){#f3-gnl-10-604}

###### 

Clinical Characteristics of the Patients

  Characteristic                            Steroid group (n=132)   Steroid-free group (n=66)   p-value
  ----------------------------------------- ----------------------- --------------------------- ---------
  Age, yr                                   49.55±0.75              50.23±1.02                  0.599
  Sex, male/female                          117/15                  62/4                        0.232
  BMI, kg/m^2^                              22.47±0.23              22.60±0.30                  0.751
  Transplantation type                                                                          0.061
   LDLT                                     27                      5                           
   DDLT                                     92                      52                          
   DCD                                      13                      9                           
  Cold ischemia time, hr                                                                        
   LDLT                                     1.31±0.265              1.21±0.095                  0.872
   DDLT                                     9.72±0.26               10.03±0.317                 0.462
   DCD                                      9.47±0.754              8.8±1.135                   0.616
  DM pre-LT                                 12 (9.1)                7 (10.6)                    0.733
  Hypertension pre-LT                       13 (9.8)                4 (6.1)                     0.370
  MELD score                                13.20±0.54              13.47±1.04                  0.798
  Child score                               7.47±0.20               6.94±0.34                   0.204
  HBV-DNA                                                                                       0.191
   \<10^3^ copies/mL                        65                      39                          
   ≥10^3^ copies/mL                         67                      27                          
  Pretransplant AFP                         3,986.31±1,219.74       2331.96±1784.25             0.461
  Hangzhou criteria, fulfilling/exceeding   96/36                   44/22                       0.377
  Milan criteria, fulfilling/exceeding      53/79                   33/33                       0.188
  Tumor characteristics                                                                         
   Size of greatest tumor, cm               4.60±0.26               4.39±0.43                   0.661
   No. of tumors                            3.89±0.77               1.88±0.18                   0.066
  Histological differentiation                                                                  0.181
   Well differentiated                      3                       5                           
   Moderately differentiated                64                      28                          
   Poorly differentiated                    65                      33                          
  Vascular invasion                         31                      17                          0.358
  Tacrolimus levels post-LT, ng/mL                                                              
   7 Day                                    7.59±0.55               6.95±0.48                   0.384
   14 Day                                   9.00±0.50               9.55±0.49                   0.433
   30 Day                                   7.76 ±0.37              6.20±0.29                   0.001
   60 Day                                   8.66±0.36               7.24±0.33                   0.005
   90 Day                                   7.43±0.42               7.20±0.67                   0.756
   120 Day                                  6.85±0.49               6.50±0.65                   0.668

Data are presented as mean±SD or number (%).

BMI, body mass index; LDLT, liver living donor liver transplantation; DDLT, deceased donor liver transplantation; DCD, donation after cardiac death; DM, diabetes mellitus; LT, liver transplantation; MELD, Model for End-stage Liver Disease; HBV, hepatitis B virus; AFP, alpha fetoprotein.

###### 

Complications after Liver Transplantation

                    Steroid group (n=132)   Steroid-free group (n=66)   p-value
  ----------------- ----------------------- --------------------------- ---------
  Acute rejection   8 (6.1)                 2 (3.0)                     0.359
  Hypertension      6 (4.5)                 1 (1.5)                     0.276
  Infection                                                             
   Viruses          3 (2.3)                 2 (3.0)                     0.742
   Tuberculosis     1 (0.76)                1 (1.5)                     0.615
   Bacteria         6 (4.5)                 6 (9.1)                     0.206
   Fungus           3 (2.3)                 2 (3.0)                     0.749
  NODM              37 (28.0)               14 (21.2)                   0.301
  HBV recurrence    18 (13.6)               2 (3.0)                     0.020
  Hyperlipidemia    7 (5.3)                 2 (3.0)                     0.469
  HCC recurrence    61 (46.2)               24 (36.4)                   0.187
  ERD               11 (8.3)                3 (4.5)                     0.327
  EAD               6 (4.5)                 2 (3.0)                     0.610

Data are presented as number (%).

NODM, new-onset diabetes mellitus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ERD, early renal dysfunction; EAD, early allograft dysfunction.
